文献速递免疫规划传染病防控与疫情报告

希腊2013-2014至2018-2019六个季节流感疫苗对实验室确诊流感住院的保护效果:汇总分析

Influenza vaccine effectiveness against hospitalization with laboratory-confirmed influenza in Greece: A pooled analysis across six seasons, 2013-2014 to 2018-2019.
PubMed 文献 · Vaccine · 2020-02-06

该研究采用检测阴性设计,分析希腊六个季节(2013-2014至2018-2019)因流感住院患者的监测数据,共纳入3882例阳性病例和5895例阴性对照。调整后疫苗对所有流感住院的保护效果为45.5%(95%CI:31.6-56.6),对A(H1N1)pdm09为62.8%,对A(H3N2)为28.2%,对B型为45.5%。

要点

  • 六个季节调整后流感疫苗对所有流感住院的保护效果为45.5%(95%CI:31.6-56.6)。
  • 对A(H3N2)的保护效果较低,为28.2%(95%CI:12.0-41.3)。
  • 60岁及以上人群保护效果略低,重症与非重症住院患者间相似。

核心结论

  • 研究结果证实季节性流感疫苗接种具有公共卫生益处,尽管对A(H3N2)株的保护效果欠佳。
  • 持续监测疫苗保护效果至关重要,常规收集的监测数据可在这方面发挥重要价值。

研究设计与样本

  • 采用检测阴性设计,病例为RT-PCR检测流感阳性的住院患者,对照为检测阴性的住院患者。
  • 分析希腊2013-2014至2018-2019六个季节全国住院患者拭子样本,共3882例阳性病例和5895例阴性对照。
  • 使用混合效应逻辑回归估计接种流感疫苗的比值比(OR),并调整年龄、性别、住院类型(是否入住重症监护)、症状出现至采样的时间及日历时间。
  • 按年龄、住院类型、流感型/亚型及季节进行分层估计,并对部分流行株进行抗原和基因特征分析。

主要发现

  • 所有季节调整后疫苗对所有流感住院的保护效果为45.5%(95%CI:31.6-56.6)。
  • 对A(H1N1)pdm09的保护效果为62.8%(95%CI:40.7-76.7),对A(H3N2)为28.2%(95%CI:12.0-41.3),对B型为45.5%(95%CI:29.1-58.1)。
  • 60岁及以上患者的保护效果略低,重症监护内与外的住院患者保护效果相似。
  • 循环A(H1N1)pdm09和B株与疫苗株抗原性相似,而A(H3N2)株与疫苗株不相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Monitoring seasonal influenza Vaccine Effectiveness (VE) is key to inform vaccination strategies and sustain uptake. Pooling data across multiple seasons increases precision and allows for subgroup analyses, providing more conclusive evidence. Our aim was to assess VE against hospitalization with laboratory-confirmed influenza in Greece over six seasons, from 2013 to 2014 to 2018-2019, using routinely collected surveillance data. METHODS: Swab samples from hospitalized patients across the country were tested for influenza by RT-PCR. We used the test-negative design, with patients testing positive for influenza serving as cases and those testing negative serving as controls. VE was calculated as one minus the Odds Ratio (OR) for influenza vaccination, estimated by mixed-effects logistic regression and adjusted for age, sex, hospitalization type (being in intensive care or not), time from symptom onset to swabbing, and calendar time. Stratified estimates by age and hospitalization type were obtained, and also subgroup estimates by influenza type/subtype and season. Antigenic and genetic characterization of a subset of circulating influenza strains was performed. RESULTS: A total of 3,882 test-positive cases and 5,895 test-negative controls were analyzed. Across all seasons, adjusted VE was 45.5% (95% CI: 31.6-56.6) against all influenza, 62.8% against A(H1N1)pdm09 (95% CI: 40.7-76.7), 28.2% against A(H3N2) (95% CI: 12.0-41.3) and 45.5% against influenza B (95% CI: 29.1-58.1). VE was slightly lower for patients aged 60 years and over, and similar between patients hospitalized inside or outside intensive care. Circulating A(H1N1)pdm09 and B strains were antigenically similar to the vaccine strains, whereas A(H3N2) were not. CONCLUSION: Our results confirm the public health benefits from seasonal influenza vaccination, despite the suboptimal effectiveness against A(H3N2) strains. Continued monitoring of VE is essential, and routinely collected surveillance data can be valuable in this regard.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Mouratidou E, Lambrou A, Andreopoulou A, et al. Influenza vaccine effectiveness against hospitalization with laboratory-confirmed influenza in Greece: A pooled analysis across six seasons, 2013-2014 to 2018-2019. Vaccine. 2020. PMID: 32033848. doi:10.1016/j.vaccine.2020.01.083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。